Global Moderna Vaccine Market

Moderna Vaccine Comprehensive Study by End User (Laboratories, Hospitals, Diagnostic Centers and Clinics, Research Institutes, Others) Players and Region - Global Market Outlook to 2030

Moderna Vaccine Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.73%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Moderna Vaccine
COVID-19 Vaccine Moderna is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 Vaccine Moderna contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. COVID-19 Vaccine Moderna does not contain the virus itself and cannot cause COVID-19.COVID-19 Vaccine Moderna is given as two injections, usually into the muscle of the upper arm, 28 days apart

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR20.73%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Moderna Vaccine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Moderna, Inc. (United States), CureVac (Germany), BioNTech (Germany), Sanofi, Pfizer, GlaxoSmithKline plc, Merck & Co Inc, Inovio pharmaceuticals Inc, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Novartis AG and Moderna are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Moderna Vaccine market by and Region.



On the basis of geography, the market of Moderna Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Laboratories will boost the Moderna Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Funding for Research and Development Activities to Develop the Moderna Vaccine

Market Growth Drivers:
Growing Strategic Partnerships among Various Biotech and Pharmaceutical Firms and Rising Number of Geriatric Population and People Suffering from Preexisting Conditions including Respiratory Conditions, Diabetes, and Heart Diseases

Challenges:
Strict Government Rules and Regulations

Restraints:
Uncertainty in the Efficacy and Side Effects of Repurposed Malaria Drugs Targeting COVID-19

Opportunities:
Adoption of New Tools to Expedite Drug Discovery and Investments in Real-world Evidence by Pharmaceutical Companies

Market Leaders and their expansionary development strategies
In May 2022, Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine SpikevaxTM from Takeda to Moderna in Japan. Moderna will assume responsibility for all Spikevax™ activities, including import, local regulatory, development, quality assurance, and commercialization with the support of Takeda's distribution.
In Nov 2020, Moderna, Inc. announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.


Key Target Audience
Moderna Vaccine Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End User
  • Laboratories
  • Hospitals
  • Diagnostic Centers and Clinics
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Strategic Partnerships among Various Biotech and Pharmaceutical Firms
      • 3.2.2. Rising Number of Geriatric Population and People Suffering from Preexisting Conditions including Respiratory Conditions, Diabetes, and Heart Diseases
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Growing Funding for Research and Development Activities to Develop the Moderna Vaccine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Moderna Vaccine, by End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Moderna Vaccine (Value)
      • 5.2.1. Global Moderna Vaccine by: End User (Value)
        • 5.2.1.1. Laboratories
        • 5.2.1.2. Hospitals
        • 5.2.1.3. Diagnostic Centers and Clinics
        • 5.2.1.4. Research Institutes
        • 5.2.1.5. Others
      • 5.2.2. Global Moderna Vaccine Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Moderna Vaccine (Price)
  • 6. Moderna Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Moderna, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CureVac (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioNTech (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co Inc
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Inovio pharmaceuticals Inc
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bavarian Nordic
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mitsubishi Tanabe Pharma Corporation
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis AG
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Moderna
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Moderna Vaccine Sale, by End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Moderna Vaccine (Value)
      • 7.2.1. Global Moderna Vaccine by: End User (Value)
        • 7.2.1.1. Laboratories
        • 7.2.1.2. Hospitals
        • 7.2.1.3. Diagnostic Centers and Clinics
        • 7.2.1.4. Research Institutes
        • 7.2.1.5. Others
      • 7.2.2. Global Moderna Vaccine Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Moderna Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Moderna Vaccine: by End User(USD Million)
  • Table 2. Moderna Vaccine Laboratories , by Region USD Million (2018-2023)
  • Table 3. Moderna Vaccine Hospitals , by Region USD Million (2018-2023)
  • Table 4. Moderna Vaccine Diagnostic Centers and Clinics , by Region USD Million (2018-2023)
  • Table 5. Moderna Vaccine Research Institutes , by Region USD Million (2018-2023)
  • Table 6. Moderna Vaccine Others , by Region USD Million (2018-2023)
  • Table 7. South America Moderna Vaccine, by Country USD Million (2018-2023)
  • Table 8. South America Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 9. Brazil Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 10. Argentina Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 11. Rest of South America Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 12. Asia Pacific Moderna Vaccine, by Country USD Million (2018-2023)
  • Table 13. Asia Pacific Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 14. China Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 15. Japan Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 16. India Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 17. South Korea Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 18. Taiwan Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 19. Australia Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 20. Rest of Asia-Pacific Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 21. Europe Moderna Vaccine, by Country USD Million (2018-2023)
  • Table 22. Europe Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 23. Germany Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 24. France Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 25. Italy Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 26. United Kingdom Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 27. Netherlands Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 28. Rest of Europe Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 29. MEA Moderna Vaccine, by Country USD Million (2018-2023)
  • Table 30. MEA Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 31. Middle East Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 32. Africa Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 33. North America Moderna Vaccine, by Country USD Million (2018-2023)
  • Table 34. North America Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 35. United States Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 36. Canada Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 37. Mexico Moderna Vaccine, by End User USD Million (2018-2023)
  • Table 38. Company Basic Information, Sales Area and Its Competitors
  • Table 39. Company Basic Information, Sales Area and Its Competitors
  • Table 40. Company Basic Information, Sales Area and Its Competitors
  • Table 41. Company Basic Information, Sales Area and Its Competitors
  • Table 42. Company Basic Information, Sales Area and Its Competitors
  • Table 43. Company Basic Information, Sales Area and Its Competitors
  • Table 44. Company Basic Information, Sales Area and Its Competitors
  • Table 45. Company Basic Information, Sales Area and Its Competitors
  • Table 46. Company Basic Information, Sales Area and Its Competitors
  • Table 47. Company Basic Information, Sales Area and Its Competitors
  • Table 48. Company Basic Information, Sales Area and Its Competitors
  • Table 49. Company Basic Information, Sales Area and Its Competitors
  • Table 50. Moderna Vaccine: by End User(USD Million)
  • Table 51. Moderna Vaccine Laboratories , by Region USD Million (2025-2030)
  • Table 52. Moderna Vaccine Hospitals , by Region USD Million (2025-2030)
  • Table 53. Moderna Vaccine Diagnostic Centers and Clinics , by Region USD Million (2025-2030)
  • Table 54. Moderna Vaccine Research Institutes , by Region USD Million (2025-2030)
  • Table 55. Moderna Vaccine Others , by Region USD Million (2025-2030)
  • Table 56. South America Moderna Vaccine, by Country USD Million (2025-2030)
  • Table 57. South America Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 58. Brazil Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 59. Argentina Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 60. Rest of South America Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 61. Asia Pacific Moderna Vaccine, by Country USD Million (2025-2030)
  • Table 62. Asia Pacific Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 63. China Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 64. Japan Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 65. India Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 66. South Korea Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 67. Taiwan Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 68. Australia Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 69. Rest of Asia-Pacific Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 70. Europe Moderna Vaccine, by Country USD Million (2025-2030)
  • Table 71. Europe Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 72. Germany Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 73. France Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 74. Italy Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 75. United Kingdom Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 76. Netherlands Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 77. Rest of Europe Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 78. MEA Moderna Vaccine, by Country USD Million (2025-2030)
  • Table 79. MEA Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 80. Middle East Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 81. Africa Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 82. North America Moderna Vaccine, by Country USD Million (2025-2030)
  • Table 83. North America Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 84. United States Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 85. Canada Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 86. Mexico Moderna Vaccine, by End User USD Million (2025-2030)
  • Table 87. Research Programs/Design for This Report
  • Table 88. Key Data Information from Secondary Sources
  • Table 89. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Moderna Vaccine: by End User USD Million (2018-2023)
  • Figure 5. South America Moderna Vaccine Share (%), by Country
  • Figure 6. Asia Pacific Moderna Vaccine Share (%), by Country
  • Figure 7. Europe Moderna Vaccine Share (%), by Country
  • Figure 8. MEA Moderna Vaccine Share (%), by Country
  • Figure 9. North America Moderna Vaccine Share (%), by Country
  • Figure 10. Global Moderna Vaccine share by Players 2023 (%)
  • Figure 11. Global Moderna Vaccine share by Players (Top 3) 2023(%)
  • Figure 12. Global Moderna Vaccine share by Players (Top 5) 2023(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Moderna, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 15. Moderna, Inc. (United States) Revenue: by Geography 2023
  • Figure 16. CureVac (Germany) Revenue, Net Income and Gross profit
  • Figure 17. CureVac (Germany) Revenue: by Geography 2023
  • Figure 18. BioNTech (Germany) Revenue, Net Income and Gross profit
  • Figure 19. BioNTech (Germany) Revenue: by Geography 2023
  • Figure 20. Sanofi Revenue, Net Income and Gross profit
  • Figure 21. Sanofi Revenue: by Geography 2023
  • Figure 22. Pfizer Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Revenue: by Geography 2023
  • Figure 24. GlaxoSmithKline plc Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc Revenue: by Geography 2023
  • Figure 26. Merck & Co Inc Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co Inc Revenue: by Geography 2023
  • Figure 28. Inovio pharmaceuticals Inc Revenue, Net Income and Gross profit
  • Figure 29. Inovio pharmaceuticals Inc Revenue: by Geography 2023
  • Figure 30. Bavarian Nordic Revenue, Net Income and Gross profit
  • Figure 31. Bavarian Nordic Revenue: by Geography 2023
  • Figure 32. Mitsubishi Tanabe Pharma Corporation Revenue, Net Income and Gross profit
  • Figure 33. Mitsubishi Tanabe Pharma Corporation Revenue: by Geography 2023
  • Figure 34. Novartis AG Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG Revenue: by Geography 2023
  • Figure 36. Moderna Revenue, Net Income and Gross profit
  • Figure 37. Moderna Revenue: by Geography 2023
  • Figure 38. Global Moderna Vaccine: by End User USD Million (2025-2030)
  • Figure 39. South America Moderna Vaccine Share (%), by Country
  • Figure 40. Asia Pacific Moderna Vaccine Share (%), by Country
  • Figure 41. Europe Moderna Vaccine Share (%), by Country
  • Figure 42. MEA Moderna Vaccine Share (%), by Country
  • Figure 43. North America Moderna Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Moderna, Inc. (United States)
  • CureVac (Germany)
  • BioNTech (Germany)
  • Sanofi
  • Pfizer
  • GlaxoSmithKline plc
  • Merck & Co Inc
  • Inovio pharmaceuticals Inc
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Moderna
Select User Access Type

Key Highlights of Report


Apr 2024 169 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Moderna Vaccine Market Quantitative research analysis
Global Moderna Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Moderna, Inc. (United States), CureVac (Germany), BioNTech (Germany), Sanofi, Pfizer, GlaxoSmithKline plc, Merck & Co Inc, Inovio pharmaceuticals Inc, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Novartis AG and Moderna etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Funding for Research and Development Activities to Develop the Moderna Vaccine" is seen as one of major influencing trends for Moderna Vaccine Market during projected period 2023-2030.
The Moderna Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Moderna Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Alverine Citrate Comprehensive Study by Administration (Oral, Injection), Level (Mild, Moderate, Severe), End User (Adult, Children), Capsules (60 MG, 120 Mg, Others (300 Mg)) Players and Region - ...
$ 3500
Renal Cell Cancer Treatment Comprehensive Study by Type (Surgery, Radiation therapy, Chemotherapy, Immunotherapy, Targeted therapy, Others(Under Clinical trial)), Surgery types (Partial nephrectomy, ...
$ 3750
Shigella Vaccines Comprehensive Study by Application (Hospitals, Clinics, Academic and Research, Others), Species (Shigella Sonnei, Shigella Flexneri, Shigella Boydii, Shigella Dysenteriae) Players a...
$ 3500
Hard Capsule Gelatin Comprehensive Study by Type (Transparent, Translucent, Opaque), Application (Preparation of Drugs, Preparation of Health Care Products), Excipients used (Powder filled capsule, ...
$ 3750
Natural Cold Remedies Comprehensive Study by Type (Eucalyptus, Ashwagandha, Vitamin C, Nasal Irrigation, Herbal Supplements & Vitamins, Others), Application (Home, Ayurvedic Clinic), Form (Tablets, S...
$ 3450
Blockbuster Drugs Comprehensive Study by Type (Generic Drug, Brand Name Drug), Application (Oncology, Immunology, Autoimmune Diseases, Cardiovascular Diseases, Other), Route of Administration (Oral, ...
$ 3450